- Home
- HCM vs CNTA Comparison
HCM vs CNTA Comparison
Compare HCM & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCM
- CNTA
- Stock Information
- Founded
- HCM 2000
- CNTA 2020
- Country
- HCM Hong Kong
- CNTA United Kingdom
- Employees
- HCM N/A
- CNTA N/A
- Industry
- HCM Biotechnology: Pharmaceutical Preparations
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- HCM Health Care
- CNTA Health Care
- Exchange
- HCM Nasdaq
- CNTA Nasdaq
- Market Cap
- HCM 2.6B
- CNTA 2.3B
- IPO Year
- HCM N/A
- CNTA 2021
- Fundamental
- Price
- HCM $17.44
- CNTA $21.33
- Analyst Decision
- HCM
- CNTA Strong Buy
- Analyst Count
- HCM 0
- CNTA 11
- Target Price
- HCM N/A
- CNTA $30.60
- AVG Volume (30 Days)
- HCM 57.4K
- CNTA 1.4M
- Earning Date
- HCM 08-07-2025
- CNTA 11-11-2025
- Dividend Yield
- HCM N/A
- CNTA N/A
- EPS Growth
- HCM N/A
- CNTA N/A
- EPS
- HCM 0.53
- CNTA N/A
- Revenue
- HCM $602,197,000.00
- CNTA $15,000,000.00
- Revenue This Year
- HCM $2.73
- CNTA N/A
- Revenue Next Year
- HCM $17.33
- CNTA N/A
- P/E Ratio
- HCM $6.26
- CNTA N/A
- Revenue Growth
- HCM N/A
- CNTA 118.88
- 52 Week Low
- HCM $11.51
- CNTA $9.60
- 52 Week High
- HCM $21.50
- CNTA $23.24
- Technical
- Relative Strength Index (RSI)
- HCM 60.43
- CNTA 66.36
- Support Level
- HCM $15.51
- CNTA $21.47
- Resistance Level
- HCM $18.30
- CNTA $23.24
- Average True Range (ATR)
- HCM 0.35
- CNTA 1.27
- MACD
- HCM 0.29
- CNTA 0.47
- Stochastic Oscillator
- HCM 76.18
- CNTA 76.79
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.